Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Big Week to Set Tone for Markets Amid Investor, Fed Worries
12:45pm, Monday, 12'th Dec 2022 Investing.com
This fund beats the S&P 500 by using just 75 of its components. Here's how it works.
05:39pm, Saturday, 10'th Dec 2022 MarketWatch
A combination of quality and lower prices has worked well through bull and bear markets — it may be just the ticket for investors worried about a recession.
Ligand (LGND) Down 3% Since Last Earnings Report: Can It Rebound?
04:30pm, Wednesday, 07'th Dec 2022 Zacks Investment Research
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Syndax's (SNDX) Leukemia Drug Gets FDA Breakthrough Therapy Tag
01:24pm, Tuesday, 06'th Dec 2022 Zacks Investment Research
The FDA bestows a Breakthrough Therapy designation to Syndax's (SNDX) revumenib for treating patients with relapsed/refractory acute leukemia harboring a KMT2A rearrangement. Stock up.
Incyte (INCY) Up 3.3% Since Last Earnings Report: Can It Continue?
04:31pm, Thursday, 01'st Dec 2022 Zacks Investment Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
7 Undervalued Biotech Stocks to Buy Before They Boom
08:30pm, Tuesday, 29'th Nov 2022
You'll often hear people say that bear markets are great for finding bargains, and that's true. With the exception of energy, every major sector is in the red for the year.
Incyte (INCY) Outperforms YTD: Will the Momentum Continue?
02:45pm, Friday, 25'th Nov 2022 Zacks Investment Research
Incyte (INCY) outperforms the biotech industry in the year so far and the momentum should continue in 2023 as well.
Incyte (INCY) Outperforms YTD: Will the Momentum Continue?
11:17am, Friday, 25'th Nov 2022
Incyte (INCY) outperforms the biotech industry in the year so far and the momentum should continue in 2023 as well.
Incyte to Present at Upcoming Investor Conferences
08:00am, Thursday, 17'th Nov 2022
WILMINGTON, Del.--( BUSINESS WIRE )--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November and December:
7 Cash-Rich Stocks to Buy for Peace of Mind
02:22pm, Friday, 04'th Nov 2022
Companies of all sizes appear to be hoarding cash for the much-discussed impending recession. If we do dive into a recession, cash-rich stocks will be more than prepared for whatever slowdown comes th
2 Biotech Stocks That Could Make You Richer
01:07pm, Friday, 04'th Nov 2022 The Motley Fool
Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors.
2 Biotech Stocks That Could Make You Richer
09:07am, Friday, 04'th Nov 2022
Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors.
Incyte A Buy As Revenue From Opzelura Ramps
04:36pm, Wednesday, 02'nd Nov 2022
Incyte reported 20% y/y product revenue growth in Q3 2022. Opzelura revenue grew $38 million y/y.
Incyte (INCY) Q3 Earnings and Revenues Miss Estimates
12:35pm, Tuesday, 01'st Nov 2022 Zacks Investment Research
Incyte (INCY) delivered earnings and revenue surprises of -16.67% and 2.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Incyte's (INCY) Q3 Earnings and Revenues Miss Estimates
12:03pm, Tuesday, 01'st Nov 2022
Incyte's (INCY) earnings and revenues fall shy of estimates in the third quarter of 2022. The company tightens Jakafi's full-year net product revenue guidance.
